Ocugen Inc [NASDAQ: OCGN] slipped around -0.1 points on Monday, while shares priced at $1.54 at the close of the session, down -6.10%. The company report on April 1, 2024 at 6:08 PM that Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease.
Established Low Dose as Safe and Tolerable Dose in Current OCU410ST Clinical Trial.
Compared to the average trading volume of 7.80M shares, OCGN reached a trading volume of 8808423 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Ocugen Inc [OCGN]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for OCGN shares is $7.50 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on OCGN stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Chardan Capital Markets have made an estimate for Ocugen Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 01, 2023. While these analysts kept the previous recommendation, Mizuho raised their target price to Buy. The new note on the price target was released on August 23, 2022, representing the official price target for Ocugen Inc stock. Previously, the target price had yet another raise to $8, while ROTH Capital analysts kept a Buy rating on OCGN stock.
The Average True Range (ATR) for Ocugen Inc is set at 0.19 The Price to Book ratio for the last quarter was 6.76, with the Price to Cash per share for the same quarter was set at 0.21.
How has OCGN stock performed recently?
Ocugen Inc [OCGN] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.10. With this latest performance, OCGN shares gained by 64.53% in over the last four-week period, additionally plugging by 280.25% over the last 6 months – not to mention a rise of 74.52% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for OCGN stock in for the last two-week period is set at 63.73, with the RSI for the last a single of trading hit 60.79, and the three-weeks RSI is set at 64.76 for Ocugen Inc [OCGN]. The present Moving Average for the last 50 days of trading for this stock 0.9068, while it was recorded at 1.7040 for the last single week of trading, and 0.5770 for the last 200 days.
Ocugen Inc [OCGN]: Deeper insight into the fundamentals
Ocugen Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.08 and a Current Ratio set at 5.08.
Earnings analysis for Ocugen Inc [OCGN]
With the latest financial reports released by the company, Ocugen Inc posted -0.1/share EPS, while the average EPS was predicted by analysts to be reported at -0.1/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for OCGN.
Insider trade positions for Ocugen Inc [OCGN]
The top three institutional holders of OCGN stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in OCGN stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in OCGN stock with ownership which is approximately 5.8386%.
